Table 2.

Differences in mean Psoriasis Treatment Convenience Scale total scores at week 1 and week 8

	Week 1				Week 8
	PAD-cream	TS/gel	Difference	P value	PAD-cream	TS/gel	Difference	P value
All patients, n = 1271	39.1	36.4	2.7	< 0.0001	40.4	37	3.4	< 0.0001
BSA > 10% subgroup, n = 319	39.7	36.0	3.7	< 0.0001	41.3	37.7	3.6	< 0.0001
mPASI > 10 subgroup, n = 288	40.7	37.0	3.7	< 0.0001	40.5	36	4.5	< 0.0001
DLQI > 10 subgroup, n = 505	38.7	34,7	4.0	< 0.0001	39.3	35.3	4.0	< 0.0001
Rule of tens subgroup,a n = 705	39.0	35.1	3.8	< 0.0001	39.7	35.9	3.8	< 0.0001
High severity subgroup,b n = 104	38.9	35.4	3.5	0.0196	41.7	36.3	5.5	0.0001

MITT using last observation carried forward, while-on-treatment strategy. Differences and p values are for CAL/BDP PAD-cream vs. CAL/BDP TS/gel

TS topical suspension, MITT modified intention to treat, BSA body surface area, mPASI modified Psoriasis Area and Severity Index, DLQI Dermatology Life Quality Index, CAL calcipotriene, BDP betamethasone dipropionate, PAD polyaphron dispersion

^aRule of tens subgroup = BSA or mPASI or DLQI > 10

^bHigh severity subgroup = BSA and mPASI and DLQI > 10